Capricor Therapeutics (CAPR) saw its stock price surge 5% intraday, driven by the company's announcement of a proposed public offering of its common stock and positive developments in its Duchenne muscular dystrophy (DMD) therapy.

The biotech firm revealed plans to raise capital through the offering, with proceeds intended to support the development and manufacturing of its product candidates, including its lead therapy, Deramiocel, for DMD. The underwriters also have a 30-day option to purchase additional shares, which could further strengthen the company's financial position. Investors reacted positively to the news, reflecting confidence in Capricor's growth prospects and its ability to advance its pipeline of transformative cell and exosome-based therapeutics.